In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation - PubMed
7 hours ago
- #cell therapy
- #CAR-T cells
- #in vivo engineering
- Adoptive cell therapies using CAR-T cells are effective for hematologic malignancies.
- Traditional ex vivo T-cell engineering faces challenges like high costs and time-consuming processes.
- In vivo T-cell engineering generates functional T cells directly in patients, reducing costs and increasing scalability.
- Innovations in delivery systems include viral vectors and RNA-based platforms.
- Preclinical and clinical data show therapeutic potential, though challenges remain in solid tumor targeting and regulation.
- Authors declare no conflicts of interest, and the manuscript was collaboratively written and reviewed.